Gary C. Curhan

Gary C. Curhan

Auto-generated profile, based on publicly available information

Gary C. Curhan

Channing Division of Network Medicine and Renal Division, Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
CLCatherine E. Lovegrove
Catherine E. Lovegrove
JBJelena Bešević
Jelena Bešević
AWAkira Wiberg
Akira Wiberg
BLBen Lacey
Ben Lacey
TLThomas Littlejohns
Thomas Littlejohns
SHSarah A. Howles
Sarah A. Howles
Significance Statement: Kidney stone disease is a common disorder with poorly understood pathophysiology. Observational and genetic studies indicate that adiposity is associated with an increased risk of kidney stone disease. However, the relative contribution of general and central adipose depots and the mechanisms by which effects of adiposity on kidney stone disease are mediated have not been defined. Using conventional and genetic epidemiological techniques, we demonstrate that general and central adiposity are independently associated with kidney stone disease. In addition, one mechanism by which central adiposity increases risk of kidney stone disease is by increasing serum calcium concentration. Therapies targeting adipose depots may affect calcium homeostasis and help to prevent kidney stone disease. Background: Kidney stone disease affects approximately 10% of individuals in their lifetime and is frequently recurrent. The disease is linked to obesity, but the mechanisms mediating this association are uncertain. Methods: Associations of adiposity and incident kidney stone disease were assessed in the UK Biobank over a mean of 11.6 years/person. Genome-wide association studies and Mendelian randomization (MR) analyses were undertaken in the UK Biobank, FinnGen, and in meta-analyzed cohorts to identify factors that affect kidney stone disease risk. Results: Observational analyses on UK Biobank data demonstrated that increasing central and general adiposity is independently associated with incident kidney stone formation. Multivariable MR, using meta-analyzed UK Biobank and FinnGen data, established that risk of kidney stone disease increases by approximately 21% per one standard deviation increase in body mass index (BMI, a marker of general adiposity) independent of waist-to-hip ratio (WHR, a marker of central adiposity) and approximately 24% per one standard deviation increase of WHR independent of BMI. Genetic analyses indicate that higher WHR, but not higher BMI, increases risk of kidney stone disease by elevating adjusted serum calcium concentrations (β=0.12 mmol/L); WHR mediates 12%–15% of its effect on kidney stone risk in this way. Conclusions: Our study indicates that visceral adipose depots elevate serum calcium concentrations, resulting in increased risk of kidney stone disease. These findings highlight the importance of weight loss in individuals with recurrent kidney stones and suggest that therapies targeting adipose depots may affect calcium homeostasis and contribute to prevention of kidney stone disease.

6 December 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SCSharon G. Curhan
Sharon G. Curhan
KKKosuke Kawai
Kosuke Kawai
BYBarbara Yawn
Barbara Yawn
KRKathryn M. Rexrode
Kathryn M. Rexrode
EREric Rimms
Eric Rimms
GCGary C. Curhan
Gary C. Curhan
Background: We investigated the longitudinal association of herpes zoster (HZ), commonly known as “shingles,” and long‐term risk of stroke or coronary heart disease (CHD) among participants in 3 large US cohorts, the NHS (Nurses' Health Study), NHS II (Nurses' Health Study II), and HPFS (Health Professionals Follow‐Up Study). Methods and Results: Participants were 79 658 women in the NHS (2000–2016), 93 932 women in the NHS II (2001–2017), and 31 440 men in the HPFS (2004–2016), without prior stroke or CHD. Information on HZ, stroke, and CHD was collected on biennial questionnaires and confirmed by medical record review. Cox proportional hazards regression models were used to estimate multivariable‐adjusted hazard ratios for stroke and for CHD according to years since HZ compared with never HZ. During >2 million person‐years of follow‐up, 3603 incident stroke and 8620 incident CHD cases were documented. History of HZ was significantly and independently associated with higher long‐term risk of stroke and CHD. In pooled analyses, compared with individuals with no history of HZ, the multivariable‐adjusted hazard ratios (95% CIs) for stroke were 1.05 (0.88–1.25) among those with 1 to 4 years since HZ, 1.38 (1.10–1.74) for among those with 5 to 8 years since HZ, 1.28 (1.03–1.59) among those with for 9 to 12 years since HZ, and 1.19 (0.90–1.56) among those with ≥13 years since HZ. For CHD, the corresponding multivariable‐adjusted hazard ratios (95% CIs) were 1.13 (1.01–1.27) for 1 to 4 years, 1.16 (1.02–1.32) for 5 to 8 years, 1.25 (1.07–1.46) for 9 to 12 years, and 1.00 (0.83–1.21) for ≥13 years. Conclusions: HZ is associated with higher long‐term risk of a major cardiovascular event. These findings suggest there are long‐term implications of HZ and underscore the importance of prevention.

1 October 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
MSMichael A. Schwarzschild
Michael A. Schwarzschild
EMEric A. Macklin
Eric A. Macklin
RBRachit Bakshi
Rachit Bakshi
SBShamik Battacharyya
Shamik Battacharyya
RLRobert Logan
Robert Logan
OIon behalf of the Parkinson Study Group SURE-PD Investigators
on behalf of the Parkinson Study Group SURE-PD Investigators
Objective To investigate whether women and men with Parkinson disease (PD) differ in their biochemical and clinical responses to long-term treatment with inosine. Methods The Safety of Urate Elevation in Parkinson’s Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6.1–7.0 mg/dL) or moderate (7.1–8.0 mg/dL) serum urate elevation for up to 2 years. Parkinsonism, serum urate, and plasma antioxidant capacity were measured at baseline and repeatedly on treatment; CSF urate was assessed once, at 3 months. Here in secondary analyses results are stratified by sex. Results Inosine produced an absolute increase in average serum urate from baseline that was 50% greater in women (3.0 mg/dL) than in men (2.0 mg/dL), consistent with expected lower baseline levels in women. Similarly, only among women was CSF urate significantly greater on mild or moderate inosine (+87% [p < 0.001] and +98% [p < 0.001], respectively) than on placebo (in contrast to men: +10% [p = 0.6] and +14% [p = 0.4], respectively). Women in the higher inosine dosing group showed a 7.0 Unified Parkinson’s Disease Rating Scale (UPDRS) points/year lower rate of decline vs placebo (p = 0.01). In women, slower rates of UPDRS change were associated with greater increases in serum urate (r = −0.52; p = 0.001), and with greater increases in plasma antioxidant capacity (r = −0.44; p = 0.006). No significant associations were observed in men. Conclusions Inosine produced greater increases in serum and CSF urate in women compared to men in the SURE-PD trial, consistent with the study9s design and with preliminary evidence for slower clinical decline in early PD among women treated with urate-elevating doses of inosine. Clinicaltrials.gov identifier NCT00833690. Classification of evidence This study provides Class II evidence that inosine produced greater urate elevation in women than men and may slow PD progression in women.

27 August 2018 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RPRagnar Palsson
Ragnar Palsson
ACAnil K Chandraker
Anil K Chandraker
GCGary C Curhan
Gary C Curhan
HRHelmut G Rennke
Helmut G Rennke
GMGearoid M McMahon
Gearoid M McMahon
SWSushrut S. Waikar
Sushrut S. Waikar
Background: Whether calcium oxalate (CaOx) deposition in kidney allografts following transplantation (Tx) adversely affects patient outcomes is uncertain, as are its associated risk factors. Methods: We performed a retrospective cohort study of patients who had kidney allograft biopsies performed within 3 months of Tx at Brigham and Women’s Hospital and examined the association of CaOx deposition with the composite outcome of death or graft failure within 5 years. Results: Biopsies from 67 of 346 patients (19.4%) had CaOx deposition. In a multivariable logistic regression model, higher serum creatinine [odds ratio (OR) = 1.28 per mg/dL, 95% confidence interval (CI) 1.15–1.43], longer time on dialysis (OR = 1.11 per additional year, 95% CI 1.01–1.23) and diabetes (OR = 2.26, 95% CI 1.09–4.66) were found to be independently associated with CaOx deposition. CaOx deposition was strongly associated with delayed graft function (DGF; OR = 11.31, 95% CI 5.97–21.40), and with increased hazard of the composite outcome after adjusting for black recipient race, donor type, time on dialysis before Tx, diabetes and borderline or acute rejection (hazard ratio 1.90, 95% CI 1.13–3.20). Conclusions: CaOx deposition is common in allografts with poor function and portends worse outcomes up to 5 years after Tx. The extent to which CaOx deposition may contribute to versus result from DGF, however, cannot be determined based on our retrospective and observational data. Future studies should examine whether reducing plasma and urine oxalate prevents CaOx deposition in the newly transplanted kidney and whether this has an effect on clinical outcomes.

12 June 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
Pietro Manuel FerraroPietro Manuel Ferraro
Pietro Manuel Ferraro
YLYukun Li
Yukun Li
RBRaji Balasubramanian
Raji Balasubramanian
GCGary C. Curhan
Gary C. Curhan
ETEric N. Taylor
Eric N. Taylor
Key Points: Information on metabolomic profiles in kidney stone formers is limited. This article describes investigations of associations between plasma metabolomic profiles and the risk of incident, symptomatic kidney stones. Three novel metabolites had negative associations with kidney stones: β -cryptoxanthin and two forms of sphingomyelin. Background: Information on metabolomic profiles in kidney stone formers is limited. To examine independent associations between plasma metabolomic profiles and the risk of incident, symptomatic kidney stones in adults, we conducted prospective nested case-control studies in two large cohorts. Methods: We performed plasma metabolomics on 1758 participants, including 879 stone formers (346 from the Health Professionals Follow-Up Study [HPFS] cohort, 533 from the Nurses' Health Study [NHS] II cohort) and 879 non–stone formers (346 from HPFS, 533 from NHS II) matched for age, race, time of blood collection, fasting status, and (for NHS II) menopausal status and luteal day of menstrual cycle for premenopausal participants. Conditional logistic regression models were used to estimate the odds ratio (OR) of kidney stones adjusted for body mass index; hypertension; diabetes; thiazide use; and intake of potassium, animal protein, oxalate, dietary and supplemental calcium, caffeine, and alcohol. A plasma metabolite–based score was developed in each cohort in a conditional logistic regression model with a lasso penalty. The scores derived in the HPFS (“kidney stones metabolite score [KMS]_HPFS”) and the NHS II (“KMS_NHS”) were tested for their association with kidney stone risk in the other cohort. Results: A variety of individual metabolites were associated with incident kidney stone formation at prespecified levels of metabolome-wide statistical significance. We identified three metabolites associated with kidney stones in both HPFS and NHS II cohorts: β -cryptoxanthin, sphingomyelin (d18:2/24:1, d18:1/24:2), and sphingomyelin (d18:2/24:2). The standardized KMS_HPFS yielded an OR of 1.23 (95% confidence interval, 1.05 to 1.44) for stones in the NHS II cohort. The standardized KMS_NHS was in the expected direction but did not reach statistical significance in HPFS (OR, 1.16; 95% confidence interval, 0.97 to 1.39). Conclusions: The findings of specific metabolites associated with kidney stone status in two cohorts and a plasma metabolomic signature offer a novel approach to characterize stone formers.

1 April 2007 in The American Journal of Medicine
Verified
Journal Article
Open access
MNMark I. Neuman
Mark I. Neuman
WWWalter Willett
Walter Willett
GCGary C. Curhan
Gary C. Curhan
There are limited data regarding the role of dietary and supplemental vitamin intake and the risk of community-acquired pneumonia. We prospectively examined, during a 10-year period, the association between dietary and supplemental vitamin intake and the risk of community-acquired pneumonia among 83,165 women in Nurses' Health Study II who were between the ages of 27 and 44 years in 1991. We excluded women who had pneumonia before 1991, those who did not provide complete dietary information, or those with a history of cancer, cardiovascular disease, or asthma. Self-administered food frequency questionnaires were used to assess dietary and supplemental vitamin intake. Cases of pneumonia required a diagnosis by a physician and confirmation with a chest radiograph. The independent associations between specific vitamins and pneumonia risk were evaluated. There were 925 new cases of community-acquired pneumonia during 650,377 person-years of follow up. After adjusting for age, cigarette smoking, body mass index, physical activity, total energy intake, and alcohol consumption, there were no associations between dietary or total intake of any individual vitamin and risk of community-acquired pneumonia. Specifically, women in the highest quintile of vitamin A intake did not have a significantly lower risk of pneumonia than women in the lowest quintile (multivariate relative risk [RR]=0.88; 95% confidence interval [CI], 0.70-1.09, P for trend=.16). Similarly, vitamin C (RR=0.94; 95% CI, 0.76-1.16, P for trend=.81) and E (RR=0.95; 95% CI, 0.76-1.17, P for trend=.74) intake did not alter risk of pneumonia. Higher vitamin intake from diet and supplements is unlikely to reduce pneumonia risk in well nourished women.